Dracen Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies. The company develops novel glutamine antagonists with direct anti-tumor apoptotoc properties as well as endogenous anti-tumor immune modulatory mechanisms which increases the number of responders to anti-cancer therapy and extend survival for anti-tumor responses in areas currently evading immuno-oncology approaches.
Dracen Pharmaceuticals has raised $10.9M across 2 funding rounds on record, the most recent an undisclosed round of $2.3M announced in Aug 2023.
That round is below the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.
Dracen Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Aug 2023.
Dracen Pharmaceuticals Funding Rounds
Dracen Pharmaceuticals raised $8.6M in an undisclosed round announced in Nov 2021.
1.8 years later, an undisclosed round of $2.3M was announced in Aug 2023.
Dracen Pharmaceuticals Founders and Leadership Team
Contact details for the Dracen Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Dracen Pharmaceuticals Funding Compared to Other Health Care Startups
Dracen Pharmaceuticals' latest round of $2.3M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Dracen Pharmaceuticals in Health Care and Baltimore
Companies Similar to Dracen Pharmaceuticals
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Aptatek is developing cutting edge technologies for portable disease management devices that will improve…
Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…
Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…
For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…
Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…
Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
Dracen Pharmaceuticals Funding FAQs
What does Dracen Pharmaceuticals do?
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies. The company develops novel glutamine antagonists with direct anti-tumor apoptotoc properties as well as endogenous anti-tumor immune modulatory mechanisms which increases the number of responders to anti-cancer therapy and extend survival for anti-tumor responses in areas currently evading immuno-oncology approaches.
How much funding has Dracen Pharmaceuticals raised?
Dracen Pharmaceuticals has raised $10.9M across 2 rounds on record. The most recent is an undisclosed round of $2.3M announced in Aug 2023.
When did Dracen Pharmaceuticals last raise funding?
Dracen Pharmaceuticals' most recent funding round on record is an undisclosed round of $2.3M, announced in Aug 2023.
Who is the CEO of Dracen Pharmaceuticals?
Tom Estok is listed as CEO at Dracen Pharmaceuticals.
Where is Dracen Pharmaceuticals headquartered?
Dracen Pharmaceuticals is based in Baltimore, Maryland, United States.
How many employees does Dracen Pharmaceuticals have?
Dracen Pharmaceuticals is in the 251-500 employee band.
How does Dracen Pharmaceuticals' funding compare to other Health Care startups?
Dracen Pharmaceuticals' latest round of $2.3M is below the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.
About FundedIQ's Dracen Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Dracen Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.